Relacorilant (Lifyorli)
Small molecule
Also known as CORT125134
Evidence outlook
Approved: Ovarian Cancer (label: platinum-resistant, with nab-paclitaxel, after one to three prior regimens)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Cushing's Syndrome · Phase 3 · under FDA review
Company guidance: regulatory decision expected fourth quarter of 2026 (Corcept Therapeutics, 18 Sep 2026). “In this press release, forward-looking statements include statements concerning: relacorilant’s safety profile and potential as a treatment for patients with platinum-resistant ovarian cancer; the anticipated timing and outcome of the EC’s review of the CHMP opinion, including the potential for the EC to approve our marketing application in the fourth quarter of 2026; and Corcept’s intent to make the benefits of glucocorticoid receptor antagonism available to patients in the EU.” Source ↗
Company guidance: data expected next year (Corcept Therapeutics, 29 Jul 2026). “STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO – Results expected by the end of next year” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ROSELLA NCT05257408 · Ovarian Cancer Patients were randomized to a nab-paclitaxel active comparator and the primary endpoints, progression-free survival and overall survival, are hard cancer outcomes. Both reached statistical significance in the favorable direction in 381 patients. The trial had no blinding, so it is graded moderate and not strong. Registry: NCT05257408 | 3 | Progression-free Survival as Assessed by BICR (Up to 24 months from enrollment of the last patient); Overall survival (Up to 24 months from enrollment of the last patient) 2025-03-31 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Glucocorticoid receptor drugs
albuterol / budesonide, Beclomethasone (QVAR), Betamethasone Dipropionate Emollient Spray, Budesonide (Entocort EC), budesonide (Ortikos) and 17 more. Compare all 23 Glucocorticoid receptor drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Cushing's Syndrome: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Relacorilant (Lifyorli): this drug | Phase 3 | Small molecule | Glucocorticoid receptor | Partial signal | NCT04308590: Change in Average 24-hour SBP (Baseline and Week 22): Relacorilant -5.56 mm Hg (95% CI -10.459 to -0.659) vs Placebo -2.89 mm Hg (95% CI -6.794 to 1.006) missed | |
| Albuterol / Budesonide (Airsupra) | Approved(overall) | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Beclomethasone (QVAR) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Betamethasone Dipropionate Emollient Spray (Sernivo) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Entocort EC) | Approved(overall) | Small molecule | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Ortikos) | ApprovedUS marketing discontinued (overall) | — | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Uceris Rectal Foam) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide MMX (Uceris) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ciclesonide (Alvesco) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone (Dextenza) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate (Arnuity Ellipta) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved(overall) | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved(overall) | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Foam (Lexette) | ApprovedUS marketing discontinued (overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Lotion (Bryhali) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone (Cortenema) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone Acetate (Cortifoam) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Mifepristone (Korlym) | Approved | Small molecule | Progesterone receptor; Glucocorticoid receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Lodotra (Rayos) | US approval withdrawn(overall) | — | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Clofutriben | Phase 2 | Small molecule | 11-beta-HSD1 | not yet graded | No reviewed efficacy summary in this indication | |
| Dazucorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Relacorilant (Lifyorli) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
September 2027 (1)
What to watch
October 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (1)
December 2028 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent